Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015 DryLet, LLC ... in applications such as animal waste reduction, bioremediation, ... reduction in wastewater treatment plants and restaurant kitchen ... at the National Restaurant Association’s NRA Show 2015, ... Representatives of the company will be available to ...
(Date:4/24/2015)... -- Navitas Life Sciences is delighted to announce the appointment of ... Services. Shalabh is a proven leader in Life Science consulting ... as well as a Strategy consultant at Accenture. ... ... to welcome Shalabh into this critical role and also as ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 Athena San ... development of executive women in San Diego’s technology and ... 17th Annual Pinnacle Awards at their Gala on April ... Hotel. Register now at http://athenasd.org/events/ , The ... the Athena San Diego vision of fostering networking, risk ...
(Date:4/23/2015)... Six startups from Russia traveled to ... part of the U.S.-Russia Innovation Corridor (USRIC) program. ... startups to participate in the program since the ... University of Maryland (UMD) signed a Memorandum of ... in the biomedical industry in 2013. , Supported ...
Breaking Biology Technology:DryLet to Showcase Bio-React at the National Restaurant Association’s NRA Show 2015 May 16-19, 2015 in Chicago, Illinois 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4
... Calif., March 10 VIASPACE Inc. (OTC ... Patent and Trademark Office issued patent number 7, 499,169 ... covers detection and measurement of water vapor (humidity) in ... combustion processes such as automobiles and factory smokestacks. ...
... Alternext US: CVM) announced today that it is ... allow drugs developed using stem cells and other biological ... their shelf life. The availability of this new ... time to market by eliminating complicated and time consuming ...
... Reduce the Risks of DVT to Mark U.S. House ... The Coalition to Prevent DVT today announced the launch ... about deep-vein thrombosis (DVT) and to encourage dialogue between ... condition. A customized recreational vehicle will visit hospitals ...
Cached Biology Technology:VIASPACE Granted US Patent 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 2The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 3The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 4The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment 5
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... needed to remove pollutants from water. RUB researchers led ... different countries in order to develop a photocatalyst that ... they combine sunlight-absorbing semiconductors and nanostructured materials which they ... implement the newly developed photocatalysts into a liquid paint ...
... announce the full integration of its open access ... Pensoft,s vision for the long-term availability of open access ... Archive guarantees Pensoft,s journals will remain intact, securely stored, ... Pensoft is participating in the international Global LOCKSS Network ...
... Arizona has taken the lead in joining the growing ... economies by creating water technology innovation clusters. Water ... serve as catalysts for economic development and protection one ... University,s latest show of support for a regional water ...
Cached Biology News:Painting with catalysts: Nano-engineered materials for detoxifying water by use of sunlight 2Research secured for the future: Pensoft Publishers takes on CLOCKSS archival technology 2University of Arizona Engineering College pursues water technology innovation cluster 2University of Arizona Engineering College pursues water technology innovation cluster 3University of Arizona Engineering College pursues water technology innovation cluster 4
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... The economical ICS-90 uses continuous chemical ... to give you fast, accurate determinations of ... ranges. Easy to operate, quick to equilibrate, ... the compact ICS-90 helps you achieve maximum ...
... MATra-si Reagent optimized for siRNA applications, ... loaded with the nucleic acid of interest. ... dose is then rapidly drawn towards and ... efficient transfection. MATra-si Reagent can be used ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
Biology Products: